Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023)
Gilead Sciences (GILD) posted Income from Non-Controlling Interests of -$12.0 million for Q4 2023, down 50.0% quarter-over-quarter from -$8.0 million in Q3 2023, and down 71.43% year-on-year from -$42.0 million in Q4 2022.
Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023) Analysis & Trends
Gilead Sciences (GILD) has reported Income from Non-Controlling Interests for 15 consecutive years, with -$12.0 million the latest figure, recorded in Q4 2023.
- Income from Non-Controlling Interests for Q4 2023 came in at -$12.0 million, down 71.43% year-over-year; the trailing twelve-month figure through Sep 2024 was -$12.0 million (up 74.47% YoY), and the FY2023 annual result was -$52.0 million, down 100.0% from the prior year.
- Income from Non-Controlling Interests was -$12.0 million for Q4 2023 at Gilead Sciences, down from -$8.0 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$3.0 million in Q3 2019 and troughed at -$26.0 million in Q1 2023.
- Average Income from Non-Controlling Interests over 5 years is -$7.9 million, with a median of -$7.0 million recorded in 2019.
- Year-over-year, Income from Non-Controlling Interests slumped 800.0% in 2019 and soared 50.0% in 2022.
- Over 5 years, Income from Non-Controlling Interests stood at -$7.0 million in 2019, then changed by 0.0% to -$7.0 million in 2020, then advanced by 14.29% to -$6.0 million in 2021, then slipped by 16.67% to -$7.0 million in 2022, then plunged by 71.43% to -$12.0 million in 2023.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$12.0 million in Q4 2023, -$8.0 million in Q3 2023, and -$6.0 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 2.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -12.00 Mn |
| Sep 30, 2023 | -8.00 Mn |
| Jun 30, 2023 | -6.00 Mn |
| Mar 31, 2023 | -26.00 Mn |
| Dec 31, 2022 | -7.00 Mn |
| Sep 30, 2022 | -3.00 Mn |
| Jun 30, 2022 | -9.00 Mn |
| Mar 31, 2022 | -7.00 Mn |
| Dec 31, 2021 | -6.00 Mn |
| Sep 30, 2021 | -6.00 Mn |
| Jun 30, 2021 | -5.00 Mn |
| Mar 31, 2021 | -7.00 Mn |
| Dec 31, 2020 | -7.00 Mn |
| Sep 30, 2020 | -7.00 Mn |
| Jun 30, 2020 | -7.00 Mn |
| Mar 31, 2020 | -13.00 Mn |
| Dec 31, 2019 | -7.00 Mn |
| Sep 30, 2019 | -3.00 Mn |
| Jun 30, 2019 | -5.00 Mn |
| Mar 31, 2019 | -7.00 Mn |